cancer genetic News
-
bit.bio CEO Dr Mark Kotter speaking about challenging biology at the TEDxCambridgeUniversity ‘Untangling networks’ event
On Saturday 20 March 2021, bit.bio CEO and founder Mark Kotter was a speaker at the TEDxCambridgeUniversity ‘Untangling networks’ event. Dr Kotter was speaking about his work as a neurosurgeon, stem cell biologist and an entrepreneur. Many of the conditions he faces as a doctor, whether they are cancers, genetic or degenerative conditions, need more than a scalpel and screws or ...
By bit.bio
-
ATMP Sterility Testing
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
-
Agilent Technologies Shares Vision for Precision Genomics at ASHG 2015
Agilent Technologies Inc. (NYSE: A) is sharing its vision for precision medicine this week at the annual meeting of the American Society of Human Genomics. The conference, held in Baltimore, Maryland, is a forum for discussing recent advances in all areas of human genetics. "As new technologies and greater understanding of the causes and pathways of diseases are moving through the ...
-
SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies
SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has raised SEK 106 million (€10.5 million) in a Series A2 financing from both existing and new investors. The Series A2 round was led by Segulah Medical Acceleration and the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures. ...
-
Thermo Fisher Scientific`s Response to COVID-19 Continues to Expand to Support Development and Production of Therapeutics and Vaccines
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects ...
-
Cancer Genomic Screening Program LC-SCRUM-Asia Adopts Latest Thermo Fisher Scientific NGS Solutions
LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific's Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia. The next-generation sequencing (NGS) solutions will be used in two prospective, observational projects to support the development of future therapeutics and diagnostics for non-small ...
-
OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors
A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL LAUNCH OF THE ONCODEEP KIT DURING THE ESMO ...
By OncoDNA S.A.
-
Recently Published Apps
GRIDSS/PURPLE/LINX Workflow, used for somatic genomic rearrangement detection and classification on WGS data. This workflow takes a pair of matched tumor/normal BAM files and produces allele-specific copy number of every base of the genome, overall sample purity and ploidy, annotated SV clusters and gene fusion predictions. Moreover, it outputs detailed visualisations of the rearrangements in ...
-
OncoDNA and Synlab Partner to Facilitate Access to Comprehensive Biomarker Testing for Cancer Therapy Selection in Germany
SYNLAB LABORATORIES TO PERFORM ONCODEEP® BIOMARKER TEST TO HELP DOCTORS DECIDE ON THE MOST EFFECTIVE TREATMENT FOR THEIR CANCER PATIENTS ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY A PARTNERSHIP WITH SYNLAB, EUROPE’S LEADING CLINICAL LABORATORY AND MEDICAL DIAGNOSTIC SERVICES PROVIDER. ...
By OncoDNA S.A.
-
Director of Breast Surgery at NAPBC Accredited Facility Realizes Clinical Value of MarginProbe® in Very First Case
The new Director of Breast Surgery and Women’s Health for the breast surgery center at the Albert Einstein Healthcare Network has a very simple reason for dedicating his life to his profession. “I became a surgeon because when I see a problem, I want to fix it, and with surgery we’re often the last line of defense when dealing with breast cancer,” Dr. Archit Naik admitted. ...
-
Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel
Molecular Health GmbH announced today that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd. under which FALCO biosystems will use the products MH Guide/BRCA and MH Guide/Mendel to evaluate inherited genetic variants of BRCA1/2 and other heritable cancer-associated genes. Inherited genetic variants can predispose an individual to cancer. Hereditary Breast and Ovarian ...
-
OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors
UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. THE KIT OFFERS A COMPLETE WORKFLOW SOLUTION WHICH ENABLES LABORATORIES WITH NGS ...
By OncoDNA S.A.
-
New Clinical Trial for Treatment in Prostate Cancer Patients with Specific Genetic Biomarkers
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. Treatment can involve radiation therapy, surgery, and/or hormone ...
By MiraDx
-
C2i Genomics Partners with OncoDNA to Bring AI-Powered Liquid Biopsy for Cancer Diagnostics Across Europe
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers ...
By OncoDNA S.A.
-
SAGA Diagnostics appoints Peter Collins as Chief Executive Officer
SAGA Diagnostics AB, (“SAGA”), a leading cancer liquid biopsy and genomic testing company, is pleased to announce the appointment of Peter Collins as Chief Executive Officer. Mr. Collins is a highly experienced entrepreneur with over 30 years of experience in the pharma and diagnostics sector. He joins SAGA after successful executive roles at major players in the liquid biopsy field ...
-
Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
Surgeon Explains the Importance of Preserving the Breast During Cancer Treatment through Education, the Latest Technology—and an Artistic Touch
Dr. Elizabeth Revesz has a unique background as an artist and sculptor. She was able to translate her precision, and her ability to see things in three dimensions, into a highly successful career in medicine. But once in the medical field, Dr. Revesz went further to find her true calling. “Medicine is great, but surgery is actually where I feel the most comfortable,” the physician ...
-
Proof of concept SAGAsafe® 24-plex ultrasensitive compatibility demonstrated on naica® Prism 6 dPCR instrument
SAGA Diagnostics AB, “SAGA”, a leading cancer liquid biopsy and genomic testing company, adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society of Human Genetics (ASHG) on October 14. Chief Operating Officer Dr. Lao Saal, MD PhD, ...
-
T-Cure bioscience announces U.S. FDA clearance of investigator – initiated clinical trial for KK-LC-1 TCR-T against multiple solid tumors
LOS ANGELES, CA, September 15, 2021 T–Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR–T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I clinical study evaluating a TCR–based ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you